search
Back to results

Study of Iguratimod in Sjögren's Syndrome

Primary Purpose

Sjogren's Syndrome

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Iguratimod
Sponsored by
Peking Union Medical College Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sjogren's Syndrome focused on measuring Sjogren's Syndrome, Iguratimod

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • A diagnosis of Sjogren's syndrome according to the revised American-European Consensus Group (AECG) criteria
  • Positive dry eyes and (or) dry mouth symptoms
  • Hyperglobulinemia

Exclusion Criteria:

  • Complicated with other systemic autoimmune diseases
  • Severe complications of Sjogren's syndrome
  • Glucocorticosteroid therapy, systemic immunosuppressant therapy, or biological agents therapy within 3 months prior to the screening visit
  • Active infections or chronic infectious diseases
  • A history of malignancies
  • Pregnancy or breathfeeding
  • Inability to comply with the study protocol for any other reason

Sites / Locations

  • Peking Union Medical College HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Iguratimod

Arm Description

Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.

Outcomes

Primary Outcome Measures

ESSDAI improvement
The change from baseline in ESSDAI (EULAR Sjogren's Syndrome Disease Activity Index) score at 24 weeks.
ESSPRI improvement
The change from baseline in ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score at 24 weeks.

Secondary Outcome Measures

Unstimulated salivary flow rate
The change from baseline in unstimulated salivary flow rate at 24 weeks.
Schimer's test
The change from baseline in Schimer's test at 24 weeks.
SF-36
The change from baseline in SF-36 score at 24 weeks.
HAQ
The change from baseline in HAQ score at 24 weeks.
Immunoglobulins
The change from baseline in IgG, IgM and IgA levels at 24 weeks.
Rheumatoid Factors
The change from baseline in titer of rheumatoid factors at 24 weeks.

Full Information

First Posted
January 15, 2017
Last Updated
January 15, 2017
Sponsor
Peking Union Medical College Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03023592
Brief Title
Study of Iguratimod in Sjögren's Syndrome
Official Title
A Preliminary Efficacy Study of Iguratimod in Patients With Sjögren's Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 2017 (undefined)
Primary Completion Date
February 2018 (Anticipated)
Study Completion Date
April 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking Union Medical College Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A single-center, self-control, open-label study of efficacy and safety of Iguratimod in patients with Sjögren's Syndrome
Detailed Description
In this study, patients with Sjögren's Syndrome are enrolled and received Iguratimod 25 mg twice a day for 24 weeks. The differences of ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score, ESSPRI(EULAR Sjogren's Syndrome Patient Reported Index) score, unstimulated salivary flow rate, Schirmer's test SF-36 score and HAQ score between baseline and week 24 are evaluated to determine the efficacy of Iguratimod in patients with Sjögren's Syndrome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sjogren's Syndrome
Keywords
Sjogren's Syndrome, Iguratimod

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Iguratimod
Arm Type
Experimental
Arm Description
Patients are treated with Iguratimod 25 mg Twice a day for 24 weeks.
Intervention Type
Drug
Intervention Name(s)
Iguratimod
Other Intervention Name(s)
T-614
Intervention Description
Iguratimod 25 mg orally twice a day for 24 weeks
Primary Outcome Measure Information:
Title
ESSDAI improvement
Description
The change from baseline in ESSDAI (EULAR Sjogren's Syndrome Disease Activity Index) score at 24 weeks.
Time Frame
week 24
Title
ESSPRI improvement
Description
The change from baseline in ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) score at 24 weeks.
Time Frame
week 24
Secondary Outcome Measure Information:
Title
Unstimulated salivary flow rate
Description
The change from baseline in unstimulated salivary flow rate at 24 weeks.
Time Frame
week 24
Title
Schimer's test
Description
The change from baseline in Schimer's test at 24 weeks.
Time Frame
week 24
Title
SF-36
Description
The change from baseline in SF-36 score at 24 weeks.
Time Frame
week 24
Title
HAQ
Description
The change from baseline in HAQ score at 24 weeks.
Time Frame
week 24
Title
Immunoglobulins
Description
The change from baseline in IgG, IgM and IgA levels at 24 weeks.
Time Frame
week 24
Title
Rheumatoid Factors
Description
The change from baseline in titer of rheumatoid factors at 24 weeks.
Time Frame
week 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of Sjogren's syndrome according to the revised American-European Consensus Group (AECG) criteria Positive dry eyes and (or) dry mouth symptoms Hyperglobulinemia Exclusion Criteria: Complicated with other systemic autoimmune diseases Severe complications of Sjogren's syndrome Glucocorticosteroid therapy, systemic immunosuppressant therapy, or biological agents therapy within 3 months prior to the screening visit Active infections or chronic infectious diseases A history of malignancies Pregnancy or breathfeeding Inability to comply with the study protocol for any other reason
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hua Chen, Dr.
Phone
86-10-69158797
Email
chenhua@pumch.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan Zhao, Dr.
Organizational Affiliation
Peking Union Medical College Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hua Chen, Dr.
Phone
86-10-69158797
Email
chenhua@pumch.cn
First Name & Middle Initial & Last Name & Degree
Yan Zhao, Dr.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of Iguratimod in Sjögren's Syndrome

We'll reach out to this number within 24 hrs